What is Aptevo Therapeutics?
Aptevo Therapeutics operates at the intersection of advanced molecular biology and oncology, specializing in the development of novel therapeutic candidates. The company's core value proposition is anchored in its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. These modular protein-based platforms are engineered to create bispecific antibodies that enhance the immune system's ability to target and eliminate malignant cells. By focusing on high-unmet-need indications, Aptevo Therapeutics aims to redefine standard-of-care protocols, positioning itself as a critical player in the next generation of cancer immunotherapy. The firm's strategic focus remains on optimizing therapeutic efficacy while maintaining a scalable manufacturing framework for its diverse pipeline of candidates.
How much funding has Aptevo Therapeutics raised?
Aptevo Therapeutics has raised a total of $40.5M across 4 funding rounds:
Debt
$35M
Other Financing Round
$2M
Share Placement
$2M
Grant
$1.5M
Debt (2016): $35M with participation from MidCap Financial
Other Financing Round (2025): $2M, investors not publicly disclosed
Share Placement (2025): $2M, investors not publicly disclosed
Grant (2026): $1.5M, investors not publicly disclosed
Key Investors in Aptevo Therapeutics
MidCap Financial
A specialized middle-market lender providing flexible debt financing solutions tailored to the unique capital requirements of growth-stage healthcare and life sciences companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Aptevo Therapeutics?
With the recent influx of capital, Aptevo Therapeutics is well-positioned to accelerate its clinical development milestones and expand its research capabilities. The strategic deployment of these funds will likely prioritize the advancement of lead candidates through Phase II and Phase III trials, while simultaneously refining the ADAPTIR-FLEX platform to increase the speed of drug discovery. As the company transitions into a more mature operational phase, management is expected to focus on potential licensing agreements and collaborative research initiatives to maximize the commercial footprint of its immuno-oncology portfolio. Sustained investment in R&D infrastructure will be paramount to maintaining its competitive edge in the rapidly evolving biotech sector.
See full Aptevo Therapeutics company page
